We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CNBX market cap is 238.31k. The company's latest EPS is USD -0.0223 and P/E is -0.45.
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 7k | 0 | 0 | 410k | 130k |
| Operating Income | -3.04M | -2.6M | -2.95M | -931k | -583k |
| Net Income | -7.47M | -3.19M | -3.72M | -3.71M | -695k |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.22M | 3.08M | 811k | 499k | 31k |
| Total Liabilities | 454k | 1.27M | 2.44M | 2.52M | 2.51M |
| Total Equity | 1.77M | 1.81M | -1.63M | -2.02M | -2.48M |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.78M | -2.49M | -1.68M | -113k | -244k |
| Investing | 3.29M | 645k | 25k | 25k | 114k |
| Financing | N/A | 2.46M | 390k | 100k | 27k |
| Market Cap | 238.31k |
| Price to Earnings Ratio | -0.45 |
| Price to Sales Ratio | 2.38 |
| Price to Cash Ratio | 12.5 |
| Price to Book Ratio | -0.13 |
| Dividend Yield | - |
| Shares Outstanding | 31.11M |
| Average Volume (1 week) | 15.15k |
| Average Volume (1 Month) | 44.41k |
| 52 Week Change | -54.94% |
| 52 Week High | 0.0199 |
| 52 Week Low | 0.005 |
| Spread (Intraday) | 0.16 (97.87%) |
| Company Name | CNBX Pharmaceuticals Inc (PK) |
| Address |
5348 vegas drive las vegas, nevada 89108 |
| Website | https://www.cnbxpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
